Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen, a leader in peripheral nerve repair, will participate in the 77th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 29 to October 1, 2022, in Boston. The company will host a symposium on nerve reconstruction data on September 30, featuring insights from recent trials. Attendees can engage in hands-on demonstrations at Booth #815 and meet top scientists at the Innovation Lab. Additionally, Axogen supports various ASSH initiatives, including scholarships and skills bootcamps, reflecting its commitment to advancing nerve repair solutions.
Axogen reported Q2 2022 net revenue of $34.5 million, a 3% increase year-over-year, with a 9% increase when excluding Avive revenue. Gross margin improved to 81.8%, up from 78.9% in Q2 2021. The adjusted net loss narrowed to $2.6 million, or $0.06 per share. Cash and equivalents decreased to $64.3 million, primarily due to investments in a new processing facility. Axogen anticipates 2022 revenue between $135 million and $142 million, indicating 10% to 15% growth, with full-year gross margin expected above 80%.
Axogen, a leader in peripheral nerve injury solutions, announces that CEO Karen Zaderej will present at the Canaccord Genuity's 42nd Annual Growth Conference in Boston on August 10, 2022, at 12:30 p.m. ET. The presentation will be webcast live on the company's Investors page, with a replay available for 90 days.
Axogen focuses on developing technologies for nerve regeneration, offering products like Avance® Nerve Graft and Axoguard®, designed to restore nerve function and improve patient quality of life.
Axogen (AXGN) has announced organizational updates aimed at enhancing market development and innovation following strong preliminary second-quarter revenue of approximately $34.4 million, a 2% increase year-over-year. Changes include the sales team reporting directly to CEO Karen Zaderej and plans to appoint a new chief marketing officer. The company reaffirms its full-year revenue guidance of $135 million to $142 million with a gross margin above 80%. Further financial details will be released on August 3, 2022.
William Burke has joined the Axogen Board of Directors as chair of the Audit Committee, effective July 11, 2022. With over 25 years of experience in the medical technology sector, Burke has held senior roles at companies like Haemonetics, Medtronic, and Covidien. His extensive background in finance and business development is expected to strengthen Axogen’s leadership. Burke expressed excitement about contributing to Axogen's mission to improve patient outcomes in peripheral nerve repair, aligning with the company's innovative surgical solutions.
Axogen, a leader in surgical solutions for peripheral nerve injuries, announced presentations by CEO Karen Zaderej and CFO Peter J. Mariani at upcoming investor conferences. Mariani will speak at the Jefferies Virtual Healthcare Conference on June 9, 2022, at 10:30 a.m. ET, while Zaderej will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET. The presentations will be available via live webcast on Axogen's Investor page, with replays archived for 90 days.
Axogen, Inc. (NASDAQ: AXGN) reported first-quarter 2022 financial results with net revenue of $31.0 million, unchanged from the same period in 2021. Adjusted net loss widened to $8.5 million or $0.20 per share, compared to $3.1 million or $0.08 per share last year. Gross margin decreased to 82.1% from 83.3%. The company expects 2022 revenue between $135.0 million and $142.0 million, reflecting anticipated growth. Key developments include the successful completion of the RECON Phase 3 study for Avance Nerve Graft, providing significant clinical evidence for its use.
Axogen announced that its RECON Clinical Study successfully met its primary endpoint by demonstrating the superiority of Avance Nerve Graft in returning sensory function in digital nerve injuries. The study showed that Avance outperformed conduits, especially in gaps exceeding 12 mm, achieving significant recovery times up to 3 months faster. With results supporting a Biologics License Application (BLA) submission in late 2023, this milestone bolsters Avance's market adoption potential.
Axogen, Inc. (NASDAQ: AXGN) announced it will release its first quarter 2022 financial results on May 4, 2022, after market close. The management team will conduct a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested parties can join by calling (877) 407-0993 for the toll-free option or (201) 689-8795 directly. A live webcast will also be available on the company's website. Axogen is focused on innovative surgical solutions for peripheral nerve injuries, offering a range of products aimed at restoring nerve function.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
